• 1
    Murray CJL & Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases. Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, MA: Harvard University Press, 1996.
  • 2
    Greenberg PE, Stiglin LE & Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993;54 (11):40518.
  • 3
    WHO. Fact sheet N130, August 1996. Available at First accessed January, 1999.
  • 4
    Kind P & Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993;7(3–4):1915.
  • 5
    WHO. online database. First accessed January, 1999.
  • 6
    Lepine JP, Gastpar M & Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997; 12(1): 1929.
  • 7
    Henry JA & Rivas CA. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: depression and its treatment. PharmacoEconomics 1997;11(5):41943.
  • 8
    OECD. Health Data 1997. Paris, France: OECD, 1997.
  • 9
    Jönsson B & Bebbington PE. What price of depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164: 66573.
  • 10
    Le Pen C, Levy E & Ravily V, et al. The cost of treatment dropout in depression: a cost-benefit analysis of fluoxetine vs. Tricyclics. J Affect Disorders 1994;31: 118.
  • 11
    Hatziandreu EJ, Brown RE & Revicki DA, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. PharmacoEconomics 1994; 5(3):24968.
  • 12
    Nuijten MJ, Hardens M & Souêtre E. A Markov process analysis comparing the cost-effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. PharmacoEconomics 1995;8(2):15968.
  • 13
    Revicki DA, Brown RE & Palmer W, et al. Modelling the cost-effectiveness of antidepressant treatment in primary care. PharmacoEconomics 1995; 8(6):52440.
  • 14
    Anton SF & Revicki DA. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazadone. Psychopharmacol Bull 1995;31(2):24958.
  • 15
    Lapierre Y, Bentkover J & Schainbaum S, et al. Direct cost of depression: analysis treatment costs of paroxetine versus imipramine in Canada. Can J Psychiatry 1995;40(7):3707.
  • 16
    O'brien BJ, Novosel S & Torrance G, et al. Assessing the economic value of a new antidepressant. A willingness-to-pay approach. PharmacoEconomics 1995;7(4):3445.
  • 17
    Bentkover JD & Feighner JP. Cost analysis of paroxetine versus imipramine in major depression. PharmacoEconomics 1995;8(3):22332.
  • 18
    Einarson T, Arikian SR & Sweeney S, et al. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Therapeutics 1995;17(1):13653.
  • 19
    Einarson T, Addis A & Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. PharmacoEconomics 1997; 12(2pt2):28696.
  • 20
    Einarson TR, Addis A, Mittmann N & Iskedjian M. Meta-analysis of venlafaxine, SSRIs, and TCAs in the treatment of major depressive disorder. Can J Clin Pharmacol 1998;205–16.
  • 21
    Einarson T, Arikian SR, Casciano J & Doyle JJ. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Therapeutics 1999;21(2):296308.
  • 22
    Busse R, Howorth C & Schwartz FW. The future development of the rights based approach to health care in Germany: more rights or fewer? In: LenaghanJ (ed.). Hard Choices in Health Care. London, England: BMJ Publishing Group, 1997.
  • 23
    Ulrich V & Wille E. Healthcare reform and expenditures on drugs. The German situation. PharmacoEconomics 1996;10(Suppl. 2):818.
  • 24
    Del Vecchio C. Guaranteed entitlement to health care: an Italian point of view. In: LenaghanJ (ed.). Hard Choices in Health Care. London, England: BMJ Publishing Group, 1997.
  • 25
    Mapelli V. Cost-containment measures in the Italian health care system. PharmacoEconomics 1995; 8(2):859.
  • 26
    Who/europe. Country profile. Geneva, Switzerland: World Health Organization, 1996.
  • 27
    Rovira R. Are national drug expenditure control policies compatible with a single european market? PharmacoEconomics 1996;10(Suppl. 2):413.
  • 28
    Cabases JM. Guaranteed health care entitlement in Spain. In: LenaghanJ (ed.). Hard Choices in Health Care. London, England: BMJ Publishing Group, 1997.
  • 29
    De Marino MA, Marques JM & Velasco A. Impact of selective financing of drugs on pharmaceutical expenditures control in the province of Valladolid, Spain. PharmacoEconomics 1996;10(3):26980.
  • 30
    Caro Research. The Swedish Health Care System (a report commissioned by Wyeth-Ayerst), 1997.
  • 31
    Jönsson B. Cost-sharing for pharmaceuticals. The Swedish reimbursement system. PharmacoEconomics 1996;10(Suppl.):26774.
  • 32
    Svensson P. Guaranteed entitlement to health care: selected views on Sweden. In: LenaghanJ (ed.). Hard Choices in Health Care. London, England: BMJ Publishing Group, 1997.
  • 33
    Who/europe. Health care services. Country information. Geneva, Switzerland: World Health Organization, 1996.
  • 34
    Lenaghan J. Citizens' rights to health care in the UK. developing a national framework of entitlement. InLenaghanJ (ed.). Hard Choices in Health Care. London, England: BMJ Publishing Group, 1997.
  • 35
    Towse A. The UK pharmaceutical market. PharmacoEconomics 1996;10(Suppl. 2):1425.
  • 36
    Walley T. Drug rationing in the UK National Health Service. PharmacoEconomics 1997; 12 (3):33950.
  • 37
    AHCPR. Research about managed care. Rockville, MD: AHCPR, 1997.
  • 38
    HCFA. Managed care in medicare and Medicaid. Washington, DC: Fact Sheet, 1997.
  • 39
    PAHO. Basic country health profiles, Venezuela. Washington, DC: Country Profile, 1999.